CardioGenesis revives hopes for heart laser
This article was originally published in Clinica
Executive Summary
CardioGenesis has submitted new clinical data to support an application to market in the US its version of a controversial laser-heart therapy for angina. The amended submission is a rebuttal to an earlier knock-back from the US FDA and moves forward the unsettled debate over the proven safety and effectiveness of the technology.